Morningstar Gives Illumina a BB+ Credit Rating | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment research firm Morningstar has initiated a credit rating for Illumina of BB+, which it said reflects its negative view of the genetic analysis instrument business.

Morningstar said that although Illumina's financial position "looks solid," its rating "recognizes the fundamental advantages of competing in this industry." It also used Affymetrix's "recent downfall" in market position as a cautionary note for Illumina's creditors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.